



Publication : BioSpectrum (Print)  
Date : May 2022  
Page : 21 and 31  
Title : -



# SERUM INSTITUTE OF INDIA LTD

CONTINUES TO LEAD THE INDIAN BIOPHARMACEUTICAL INDUSTRY **AT No 1 POSITION**

Pune-based Serum Institute of India Ltd continues to lead the Indian Biopharmaceutical Industry with a revenue of **Rs 7201 crore** for the year 2020-21 followed by **Bangalore-based Biocon Ltd** with **Rs 5136 crore** and **Hyderabad-based Sanofi Healthcare India Pvt Ltd** with **Rs 1739 crore** respectively.

Top 3 Biopharma companies contribute to **45%** of the total Biopharma Industry

Top 10 Biopharma companies contribute to **73%** of the total Biopharma Industry

Top 20 Biopharma companies contribute to **90%** of the total Biopharma Industry

### BioSpectrum Top 20 BioPharma Companies 2021\*

Sr. No	Company	Revenue in 2020-21 (in Crore)	Revenue in 2019-20 (in Crore)	% growth	Category	Location	Region
1	Serum Institute of India Ltd.	7201	5014	44	India	Pune	West
2	Biocon Ltd.	5136	4487	14	India	Bengaluru	South
3	Sanofi Healthcare India Pvt. Ltd.	1,739	1,761	-1	MNC	Hyderabad	South
4	Novo Nordisk India Pvt. Ltd.	1467	1465	0	MNC	Bengaluru	South
5	Bharat Biotech International Ltd.	1439	1066	35	India	Hyderabad	South
6	Biological E Ltd.	1418	1040	36	India	Hyderabad	South
7	Reliance Life Science Pvt. Ltd.	1404	1018	38	India	Mumbai	West
8	Sanofi India Ltd.	1101	1052	5	MNC	Mumbai	West
9	Intas Pharmaceuticals Ltd.	1071	850	26	India	Ahmedabad	West
10	Glaxosmithkline Pharmaceuticals Ltd.	966	1065	-9	MNC	Mumbai	West
11	Bharat Serums & Vaccines Ltd.	942	917	3	India	Mumbai	West
12	Indian Immunologicals Ltd.	747	820	-9	India	Hyderabad	South
13	Zydus Lifesciences Ltd.	646	513	26	India	Ahmedabad	West
14	Concord Biotech Ltd.	616	543	13	India	Ahmedabad	West
15	Pfizer Ltd.	538	519	4	MNC	Mumbai	West
16	Macleods Pharmaceuticals Pvt. Ltd.	488	471	4	India	Mumbai	West
17	Lupin Ltd.	442	424	4	India	Mumbai	West
18	Abbott India Ltd.	406	395	3	MNC	Mumbai	West
19	Venkateshwara Hatcheries Pvt. Ltd. (Vaccines)	308	299	3	India	Pune	West
20	Wockhardt Ltd.	231	210	10	India	Mumbai	West

\* We have not covered some of the Biopharma companies as they are unable to participate in the BioSpectrum Survey 2020-21



REVENUE  
**₹1418 crore**



KV SUBRAMANIAM  
President



## RELIANCE LIFE SCIENCES PVT LTD

### CONTINUOUSLY DEVELOPING

Mumbai-based Reliance Life Sciences (RLS) generated revenue worth Rs 1404 crore during FY 20-21 in the biopharma space, exhibiting a growth of 38 per cent, in comparison to the revenue generation of Rs 1018 crore in the previous fiscal.

During the year, despite the daunting challenges posed by COVID-19 pandemic, Reliance Life Sciences was able to build and scale up COVID-19 RT-PCR and antibody testing facilities. The company developed and manufactured Molecular Transport Media (MTM) for safe transport of RT-PCR samples and with scalability

It also introduced 8 new products – prothrombin complex concentrate, ranibizumab, denosumab (oncology), sunitinib, sorafenib, MTM, bacteriostatic water for injection (bWFI) and sterile water for injection (sWFI); and obtained several product registrations overseas

FY 20-21 saw the company working tirelessly towards manufacturing products used to treat COVID-19 patients in intensive and critical care units in hospitals.

RLS, part of the Promoter Group of Reliance Industries Limited, ended the financial year 2021-22 on an excellent note with strong revenue growth. This high growth has been primarily driven by greater market participation, entry into newer markets, scaling up of RT-PCR testing capacities and expanding manufacturing capabilities. The company has forayed into innovative technology domains and is building a new life sciences campus at Nashik. RLS continued to grow despite the challenges posed by the second and third waves of COVID-19, by balancing biosafety with progress.

RLS envisages the new financial year 2022-23 to be even better with new avenues of growth and development, in terms of business domains, new products and new manufacturing facilities.

2020 also saw the company entering the list of vaccine developers for COVID-19. The vaccine is a protein subunit one, and is expected to be safe for all age groups. It has a unique construct, which is expected to be effective against a range of COVID-19 variants; going by data emanating from extensive in-vitro and animal studies.

RLS has launched five of the world's first biosimilars, has the largest number of biosimilars in the market in India, and the highest number of biosimilars under development globally. It has the distinction of being the first integrated manufacturer of plasma proteins in South Asia. The company has catalysed the emergence of regenerative medicine in the country, and has the highest experience with cord blood stem cell transplants in India. RLS is one of the few centres in the world offering a specialised range of tests in molecular medicine and molecular genetics.

Consistent with the diversity and depth of its initiatives, the company has a professional team of Ph.Ds, M.Ds, Engineers and Post Graduates in Science. The average age of the Reliance Life Sciences team is 35 years and 22 per cent of the employees are women. It operates state-of-the-art facilities in the life sciences domain. The flagship facility is the Dhirubhai Ambani Life Sciences Centre (DALC) in Navi Mumbai. Spread over 20 acres, DALC is among the most diverse and integrated life sciences campuses in the world. **BS**